1Gorski J, Jomes D, Haehner - Daniels B, et al . The contribution of intestinal and hepatic CYPaA to the interaction between medazolam and clarithromycin[J ]. Clin Pharmacol Tiler, 1998,64(2) : laa.
2Krecic -Shepard M,Barnas C,Slimko J ,et al .Genderspecific effects on verapamil pharmacokinetics and pharmacodynamics in humans[J] .J Clin Pharmacol,2000,40(3) : 219.
3Rohatagi S, Calic F, Harding N, et al . Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (AD1 628) after single and repeated administration in healthy male and female subjects and asthmatic patients[J ] .J Clin Pharmacol,2000, 40(11) : 1 211.
5Ducharme M, Slaughter R, Edwards D. Vancomycin pharmacokinetics in a patient population: effects of age,gender, and body weight [J ]. Ther Drug Monit, 1994,15(5):513.
6Frame B, Facca B, Nicolau D, et al .Population pharmacokinetics of continuous infusion ceftazidime[J ] . Clin Pha rmacokinet, 1999,37(4) : 343.
7Reigner BG,Welker H. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies[J ] .Antimicrob Agents Chemother , 1996,40(3) : 575.
8Yukawa E, Mine H ,Higuchi S, et al .Digoxin population pharmacokinetics from routine clinical data:roles of patient characteristics for estimating dosing regiments[J ] .J Pharm Pharmacol , 1992,44(9) : 761.
9Godfrey C,Sweeney K, Miller K, et al .The population pharmacokinetics of long - term methotrexate in rheumatoid arthritis[J ] .Br J Clin Pharmacol, 1998,46(4) :369.
10Gaudry S,Sitar D,Smyth D,et al .Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine[J].Clin Pharmacol Ther,1993,54(1) : 23.
